NEWS RELEASE

NYSE MKT to Suspend Trading Immediately in Provectus Biopharmaceuticals, Inc. (PVCT) and Commence Delisting Proceedings

10/13/2016

NEW YORK, October 13, 2016 – NYSE MKT LLC ("NYSE MKT" or the "Exchange") announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Provectus Biopharmaceuticals, Inc. (the "Company") — ticker symbol PVCT —from the Exchange. Trading in the Company's common stock on the NYSE MKT will be suspended immediately.

The Company has a warrant, which will also be delisted:

Ticker Symbol	Issue Description
PVCT WS	Warrants exercisable for one share of common stock par value $0.001 per share at an exercise price of $0.85 per share (Expiring August 30, 2021.)

NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003 of the NYSE MKT Company Guide, due to the abnormally low trading price of its common stock.

The Company has a right to a review of staff's determination to delist the common stock and warrant by a committee of the Board of Directors of the Exchange. The NYSE MKT will apply to the Securities and Exchange Commission to delist the Company's common stock and warrant upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff's decision.

Company Contact:

Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, Interim CEO, COO
Phone: 866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, SVP - Investor Relations
Phone: 212-564-4700
or
Allison + Partners
Todd Aydelotte, Managing Director
Media Relations
Phone: 646-428-0644